ArticleRheumatology international2026
Distinct immunological signatures in autoimmunity: a multi-plex analysis for the differential diagnosis of established and undifferentiated autoimmune diseases (a cross-sectional pilot study).
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical differentiation between systemic autoimmune diseases often relies on late-stage physical symptoms. This study evaluates whether serum cytokine "fingerprints" can provide earlier and more precise diagnostic clarity, particularly for clinically uncategorized patients. Serum samples from 60 patients were analyzed using a 13-plex cytokine array (Aimplex, USA). Subjects were categorized into five groups: Rheumatoid Arthritis (RA, n = 18), Multiple Sclerosis (MS, n = 12), Psoriatic Arthritis (PsA, n = 12), Allergy (n = 6), and Uncategorized (n = 12). Pro-inflammatory (Th1/Th17), regulatory (Th2), and innate cytokines were quantified in pg/mL. Distinct molecular signatures were identified for each cohort with statistically significant variations across groups (p < 0.05). MS patients exhibited significant Th17 polarization (elevated IL-17 A), while RA was characterized by the activation of the IL-6/TNF-α axis. Notably, the Uncategorized group demonstrated a median IL-6 of 8.5 pg/mL with a striking interquartile range (IQR) of 2.0-439.0 pg/mL, highlighting the presence of high-intensity inflammatory "explosions" in treatment-naïve patients. In contrast, the Allergy group was distinguished by significantly elevated regulatory IL-10 (median: 6.83 pg/mL) and minimal pro-inflammatory signaling. Discriminant analysis successfully clustered 85% of uncategorized cases into defined immunological profiles based on these profiles. Multi-plex cytokine profiling successfully differentiates between clinically similar pathologies. The extreme cytokine range in uncategorized patients suggests that molecular screening can identify high-risk individuals before formal clinical criteria are met. These findings support the integration of cytokine "fingerprinting" into personalized diagnostic and therapeutic protocols.
Indexed as
Identifiers
42377505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.